Record-breaking Animal Care sales and a landmark TSE veterinary trial drove strong H1 2025 growth, though continued losses and the need for additional funding remain. US market adoption surged, and a SEK 4.85M share issue strengthened capital.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.